Rare Insights

Exploring the ideas, innovations, and individuals shaping the future of rare disease.

5 Misconceptions About Patient Engagement in JCA – And Why Early Access Could Be Your Advantage

As EU HTA evolves under the Joint Clinical Assessment (JCA), the expectations for structured, regulator-ready patient engagement[…]

5 Patient Evidence Myths That Could Undermine Your EU JCA Strategy

The bar for patient evidence in EU health technology assessment (HTA) is rising fast. As the Joint Clinical[…]

We use cookies in order to give you the best possible experience on our website. By continuing to use this site, you agree to our use of cookies.
Accept